Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 60
Filter
Add more filters










Publication year range
1.
Peptides ; 16(2): 231-6, 1995.
Article in English | MEDLINE | ID: mdl-7784254

ABSTRACT

A rabbit antiserum was raised against the fragment (350-365) of human chromogranin B corresponding to the C-terminal end of a putative proteolytic fragment generated by the cleavage of a dibasic doublet located in position 366-367 of the precursor. A radioimmunoassay was developed. Chromatographic analysis of 10 endocrine tumor extracts (one liver metastasis of a gastrinoma, one liver metastasis of a medullary carcinoma of the thyroid, one VIPoma, one insulinoma, one nonsecreting pancreatic endocrine tumor, one local recurrence of a gut carcinoid, two pituitary gonadotropinoma, and two non-secreting pituitary adenomas) revealed the presence of two forms of immunoreactive material. The most abundant form had an apparent molecular weight of 4500 and was purified to homogeneity by successive reverse-phase HPLC chromatographies and partially sequenced. The N-terminal sequence of the peptide, established by automated Edman degradation, was A-S-E-E-E-P-E-Y-G-E-E-I-K-G-Y-P-V-Q and corresponded to the 314-332 sequence of human chromogranin B. Taking into account the specificity of the antiserum used for peptide identification, we deduced that the purified peptide was chromogranin B(314-365) and represented a new form generated by limited proteolysis of chromogranin B.


Subject(s)
Chromogranins/analysis , Endocrine Gland Neoplasms/chemistry , Peptide Fragments/analysis , Adenoma/chemistry , Amino Acid Sequence , Animals , Carcinoid Tumor/chemistry , Chromogranin B , Gastrinoma/chemistry , Humans , Immune Sera , Liver Neoplasms/chemistry , Liver Neoplasms/secondary , Molecular Sequence Data , Pancreatic Neoplasms/chemistry , Pituitary Neoplasms/chemistry , Rabbits/immunology , Radioimmunoassay , Thyroid Neoplasms/chemistry , Vipoma/chemistry
2.
Endocrinology ; 135(4): 1537-42, 1994 Oct.
Article in English | MEDLINE | ID: mdl-7925114

ABSTRACT

The expression of the messenger RNAs coding for glucagon-like peptide-I (GLP-I) receptor, VIP receptor, and pituitary adenylate cyclase-activating polypeptide (PACAP) receptor as well as the expression of the receptor proteins were demonstrated in the rat medullary carcinoma of thyroid cell line 6/23 by the following experiments: 1) RNA extraction, reverse transcriptase, and polymerase chain reaction with specific primers; 2) binding of the radiolabeled ligands [125I]GLP-I-(7-36)-NH2, [125I]PACAP-(1-27), and [125I]VIP and inhibition by, respectively, unlabeled GLP-I-(7-36)-NH2, PACAP-(1-27), and VIP; and 3) study of adenylate cyclase activation by the peptides and selective inhibition of the VIP/PACAP response by the antagonist [D-Phe2]VIP. Besides the highly selective GLP-I receptor, PACAP receptors of types I and II were present on the cell line and coupled to adenylate cyclase. PACAP stimulated the adenylate cyclase through type I and II receptors, whereas VIP interacted with type II receptors only. Messenger RNA analysis indicated that at least three splice variants of the PACAP type I receptor may be expressed in 6/23 cells.


Subject(s)
Carcinoma, Medullary/chemistry , Carcinoma, Medullary/pathology , Receptors, Cell Surface/analysis , Receptors, Glucagon , Receptors, Pituitary Hormone/analysis , Thyroid Neoplasms/chemistry , Thyroid Neoplasms/pathology , Adenylyl Cyclases/analysis , Animals , Base Sequence , Carcinoma, Medullary/genetics , DNA, Neoplasm/analysis , DNA, Neoplasm/genetics , Gene Expression Regulation, Neoplastic , Glucagon-Like Peptide-1 Receptor , Iodine Radioisotopes , Molecular Sequence Data , Polymerase Chain Reaction/methods , RNA, Messenger/analysis , RNA, Messenger/genetics , Rats , Receptors, Cell Surface/genetics , Receptors, Cell Surface/physiology , Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide , Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide , Receptors, Pituitary Hormone/genetics , Receptors, Pituitary Hormone/physiology , Receptors, Vasoactive Intestinal Peptide/analysis , Receptors, Vasoactive Intestinal Peptide/genetics , Receptors, Vasoactive Intestinal Peptide/physiology , Thyroid Neoplasms/genetics , Tumor Cells, Cultured
3.
Regul Pept ; 52(1): 53-60, 1994 Jun 16.
Article in English | MEDLINE | ID: mdl-7972932

ABSTRACT

Eleven surgical samples of gliomas (1 of grade II, 3 of grade III and 7 of grade IV) were analyzed. Calcitonin gene-related peptide (CGRP) receptors were identified by 125I-alpha h-CGRP binding in 9 cases and the presence of a CGRP-stimulated adenylate cyclase in all the 11 cases. Tracer binding was inhibited by unlabelled alpha h-CGRP (Kd of 0.3 nM), by (8-37) alpha h-CGRP (Kd of 30 nM), by (12-37) alpha h-CGRP (Kd of 3.000 nM) but not by human calcitonin. The mean density of CGRP receptors (120 fmol/mg membrane protein) was comparable to that of beta-adrenergic receptors. CGRP stimulated 1.4 to 4.7-fold (mean 2.7) the adenylate cyclase activity with a K(act) of 2.0 nM. The CGRP fragments had no intrinsic activity but inhibited the CGRP effect. The (8-37)CGRP fragment had a Ki of 30 nM. Thus, at variance with previous reports on rat and human brain membranes, that showed the presence of CGRP receptors not coupled to adenylate cyclase, we observed in human gliomas the presence of CGRP receptors that, when occupied, stimulated efficiently the adenylate cyclase activity.


Subject(s)
Adenylyl Cyclases/metabolism , Calcitonin Gene-Related Peptide/pharmacology , Glioma/enzymology , Receptors, Calcitonin Gene-Related Peptide/metabolism , Adult , Aged , Binding Sites , Enzyme Activation/drug effects , Female , Glioma/surgery , Humans , Iodine Radioisotopes , Isotope Labeling , Male , Middle Aged , Neuroglia/pathology
4.
Peptides ; 15(5): 869-74, 1994.
Article in English | MEDLINE | ID: mdl-7984507

ABSTRACT

A radioimmunoassay of human pancreastatin was developed using a rabbit antiserum that selectively recognized the C-terminal amidated end of the peptide, and it was used for the identification of the molecular forms of pancreastatin in human gut (stomach, duodenum, small intestine, colon) and endocrine tumor extracts (liver metastasis of a gastrinoma and a medullary carcinoma of thyroid, one nonsecreting pancreatic tumor, one recurrence of a gut carcinoid, one vipoma and one insulinoma). In all gut extracts, a gel filtration chromatography revealed the presence of three peaks of pancreastatin-like immunoreactivity. The predominant form eluted with an apparent molecular weight higher than that of pancreastatin. This form was also predominant in the endocrine tumors analyzed, except in the insulinoma, where a lower molecular weight form predominated. The high molecular form was further purified from a liver metastasis of a gastrinoma. The pancreastatin-like immunoreactivity eluted in all the chromatographical systems (reverse-phase, ion exchange) as a single peak that was finally purified to homogeneity and sequenced. The sequence of the first 29 N-terminal amino acids was obtained unambiguously and corresponded to the sequence 210-238 of chromogranin A. Considering the selectivity of the assay used for peptide identification, this major form was identified as the fragment 210-301 of chromogranin A. It is likely that the predominant form of pancreastatin in human gut extracts and noninsular tumors is a 92 amino acid peptide.


Subject(s)
Chromogranins/chemistry , Endocrine Gland Neoplasms/chemistry , Gastrointestinal Hormones/chemistry , Pancreatic Hormones/chemistry , Peptide Fragments/chemistry , Tissue Extracts/chemistry , Amino Acid Sequence , Animals , Chromatography, Gel , Chromogranin A , Chromogranins/genetics , DNA, Complementary/genetics , Molecular Sequence Data , Molecular Weight , Species Specificity , Swine
5.
Peptides ; 15(4): 661-5, 1994.
Article in English | MEDLINE | ID: mdl-7937342

ABSTRACT

Twenty-three human gliomas were analyzed: 13 astroglial neoplasms including three grade II, four grade III, and six grade IV tumors; seven ependymomas; and three oligodendrogliomas. A crude membrane fraction was prepared within 30 min after surgical removal of the tumors and was immediately tested for the presence of pituitary adenylate cyclase activating polypeptide (PACAP) receptors. PACAP stimulated adenylate cyclase activity in 23 tumors, but a specific binding of [125I-acetyl-His1]PACAP-27 was detected in only 16 tumors. In all cases, PACAP-27 and -38 were equipotent (Kd or Kact of 1-3 nM) and were 100- to 1000-fold more potent than VIP. PACAP stimulated threefold the adenylate cyclase activity in the presence of GTP. The results were compatible with an interaction of PACAP with a highly selective type I PACAP receptor and not with a high-affinity VIP/PACAP type II receptor. The presence of PACAP receptors on glial neoplasic opens the possibility of a control of the tumor growth by this family of peptides.


Subject(s)
Glioma/chemistry , Receptors, Pituitary Hormone/analysis , Adenylyl Cyclases/metabolism , Astrocytoma/chemistry , Enzyme Activation , Ependymoma/chemistry , Humans , Oligodendroglioma/chemistry , Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide , Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide , Receptors, Vasoactive Intestinal Polypeptide, Type I
6.
Acta Gastroenterol Belg ; 56(3-4): 261-3, 1993.
Article in English | MEDLINE | ID: mdl-8266767

ABSTRACT

The authors review the biochemical and biological properties of chromogranins and pancreastatin. Chromogranins A, B and C are acidic proteins of a molecular mass of 48,000, 76,000 and 67,000, respectively, located in the secretory granules of the neuroendocrine cells. Since large amounts of chromogranin A were found in most neuroendocrine tumours, chromogranin A plasma determination is a diagnostic tool even in silent tumours. Pancreastatin is a peptide derived from chromogranin A, which inhibits insulin secretion, exocrine pancreatic secretion and gastric acid secretion, and which stimulates glucagon secretion. Pancreastatin has different molecular forms, the major form being a high molecular form of 92 amino acids, found by the authors in human stomach- and colon extracts and in a liver metastasis of a gastrinoma. The controlled proteolysis of chromogranin A in gut neuroendocrine cells generates predominantly the high molecular weight form.


Subject(s)
Chromogranins/pharmacology , Pancreatic Hormones/pharmacology , Chromogranin A , Chromogranins/physiology , Humans , Pancreatic Hormones/physiology
7.
Mol Pharmacol ; 42(2): 347-55, 1992 Aug.
Article in English | MEDLINE | ID: mdl-1325033

ABSTRACT

In AR 4-2J rat pancreatic acinar cell membranes, receptors for the two pituitary adenylate cyclase-activating peptides (PACAP) PACAP-27 (the short version of PACAP) and PACAP-38 [the long version, with a carboxyl-terminal (residues 28-38) extension] can be subdivided into (a) type A receptors, with high affinity (Kd, 0.3-0.5 nM) for both PACAP-27 and PACAP-38, and (b) type B receptors, with high affinity for PACAP-38 (Kd, 0.3 nM) but low affinity for PACAP-27 (Kd, 20 nM). Determinants of agonist/antagonist activity in 47 PACAP-27 and PACAP-38 analogs (mono- or disubstituted in positions 1, 2, 3, 20, and 21) or amino-terminally shortened were tested by (a) the occupancy of PACAP-A receptors, preferentially labeled with [125I-N-acetyl-His1]PACAP-27, and that of PACAP-A and -B receptors, both labeled with 125I-PACAP-38, and (b) the resulting activation or inhibition of adenylate cyclase. For PACAP-A receptor recognition, deprotonated His1 was a major determinant for PACAP-27 but not PACAP-38; the Kd of 125I-PACAP-27 decreased 2.4-fold at 37 degrees between pH 6.0 and 7.5 and 3.6-fold at 15 degrees, whereas the IC50 of [N-acetyl-His1]PACAP-27 was less affected and that of PACAP(2-27), PACAP(2-38), and PACAP(1-38) was pH independent. In addition, PACAP-A receptors coupled to adenylate cyclase were much more sensitive to PACAP-38 derivatives than to PACAP-27 derivatives; for instance, [D-Phe2]PACAP-38 was a more potent antagonist (Ki, 5 nM) than [D-Phe2]PACAP-27 (Ki, 350 nM), and PACAP(6-38) was a more potent antagonist (Ki, 7 nM) than PACAP(6-27) (Ki, 300 nM). PACAP-B receptors, apart from showing high affinity for PACAP-38, displayed relatively high affinity for amino-terminally shortened PACAP-38 fragments and poor affinity for PACAP-27 and PACAP-27 fragments.


Subject(s)
Adenylyl Cyclases/metabolism , Neuropeptides/pharmacology , Peptide Fragments/pharmacology , Receptors, Cell Surface/metabolism , Receptors, Pituitary Hormone , Adenylyl Cyclase Inhibitors , Adenylyl Cyclases/drug effects , Alanine/metabolism , Amino Acid Sequence , Animals , Arginine/metabolism , Cell Membrane/drug effects , Cell Membrane/enzymology , Enzyme Activation , Hydrogen-Ion Concentration , Iodine Radioisotopes , Kinetics , Molecular Sequence Data , Neuropeptides/metabolism , Pancreas/cytology , Pancreas/drug effects , Pancreas/enzymology , Phenylalanine/metabolism , Pituitary Adenylate Cyclase-Activating Polypeptide , Protein Conformation , Rats , Receptors, Cell Surface/classification , Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide , Sequence Homology, Nucleic Acid , Serine/metabolism
8.
Eur J Biochem ; 207(1): 239-46, 1992 Jul 01.
Article in English | MEDLINE | ID: mdl-1321043

ABSTRACT

In these structure activity studies, the 46 analogs of the 27-amino-acid form of the pituitary-adenylate-cyclase-activating peptide, PACAP(1-27), and the 38-amino-acid form, PACAP(1-38), were either monosubstituted or bisubstituted at positions 1-3, 20 and 21 or N-terminally shortened. All analogs were compared on human neuroblastoma NB-OK-1 cell membranes for their ability to occupy 125I-[AcHis1]PACAP(1-27)-labelled receptors (AcHis, N alpha-acetylhistidine) and to activate adenylate cyclase (in terms of potency and intrinsic activity). The monophasic slope of dose/effect curves on both parameters suggested interaction with one class of PACAP receptor. Residues 28-38 in the C-terminally extended peptide, PACAP(1-38), played a favorable role in recognition, in that receptors coupled to adenylate cyclase were, in general, more sensitive to PACAP(1-38) analogs than to the corresponding PACAP(1-27) analogs. At variance with PACAP(6-27), PACAP(6-38) was well recognized and acted as a potent competitive antagonist (Ki 1.5 nM). Residues 1-3 were all important in enzyme activation: modification of the beta-turn potential gave full agonists (the LAla2 and DAla2 derivatives) or partial agonists (LPhe2 and DPhe2; LArg2 and DArg2; Glu3 and Asn3). Finally, a proper alpha-helix was also important: the combined substitution of Lys21/Lys22 by Gly21/Gly22 decreased the binding affinity sharply.


Subject(s)
Adenylyl Cyclases/metabolism , Cell Membrane/metabolism , Neuropeptides/pharmacology , Peptide Fragments/pharmacology , Receptors, Cell Surface/metabolism , Receptors, Pituitary Hormone , Amino Acid Sequence , Binding, Competitive , Enzyme Activation , Humans , Kinetics , Molecular Sequence Data , Neuroblastoma , Pituitary Adenylate Cyclase-Activating Polypeptide , Receptors, Cell Surface/antagonists & inhibitors , Receptors, Cell Surface/drug effects , Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide , Sequence Homology, Nucleic Acid , Signal Transduction/drug effects , Structure-Activity Relationship , Tumor Cells, Cultured
9.
Biochim Biophys Acta ; 1066(2): 245-51, 1991 Jul 22.
Article in English | MEDLINE | ID: mdl-1649637

ABSTRACT

Competition binding curves, using [125I-acetyl-His1]PACAP-27 as radioligand and dose-effect curves of adenylate cyclase activation in human SUP-T1 lymphoblastic membranes showed that PACAP-27 and PACAP-38 stimulate the enzyme through a single class of helodermin-preferring VIP receptors with the following order of potency: helodermin = [acetyl-His1]PACAP-27 greater than PACAP-38 greater than PACAP-27 greater than VIP. PACAP (6-27) (Ki 0.5-0.8 microM) and [Des-His1, Asn3]PACAP-27 (Ki 1-2 microM) acted as competitive antagonists. Using a series of 13 PACAP-27 analogues and fragments and three VIP analogues, we identified positions 1, 2, 3, 9 and 13 in PACAP-27 as being of importance for high-affinity binding. Thus, we added further evidence for considering that the present helodermin-preferring VIP receptors, when compared to a majority of VIP receptors and PACAP receptors, exhibit an original specificity pattern.


Subject(s)
Adenylyl Cyclases/metabolism , Lymphocytes/metabolism , Neuropeptides/metabolism , Receptors, Gastrointestinal Hormone/metabolism , Amino Acid Sequence , Binding Sites , Binding, Competitive , Cell Line , Cell Membrane/metabolism , Enzyme Activation , Humans , Intercellular Signaling Peptides and Proteins , Kinetics , Molecular Sequence Data , Peptides/metabolism , Pituitary Adenylate Cyclase-Activating Polypeptide , Radioligand Assay , Receptors, Vasoactive Intestinal Peptide , Vasoactive Intestinal Peptide/metabolism
10.
FEBS Lett ; 286(1-2): 133-6, 1991 Jul 29.
Article in English | MEDLINE | ID: mdl-1650711

ABSTRACT

The existence of specific receptors for the two PACAPs (Pituitary Adenylate Cyclase Activating Peptides of 27 and 38 amino acids) was previously demonstrated on membranes from the pancreatic acinar cell line AR 4-2J (Buscail et al., FEBS Lett. 202, 77-81, 1990) by [125I]PACAP-27 binding. Here we demonstrate, by comparing Scatchard analysis of saturation curves and competition binding curves obtained with [125I]PACAP-27 and [125I]PACAP-38 as radioligands, the coexistence of two classes of receptors: 1/PACAP-A receptors that recognize PACAP-27 and PACAP-38 with the same high affinity (Kd 0.3 nM) and 2/PACAP-B receptors that recognize PACAP-38 with a high affinity (Kd 0.3 nM) and PACAP-27 with a lower affinity (Kd 30 nM). These two receptors are coupled to adenylate cyclase but can be clearly distinguished by the ability of PACAP(6-27) to specifically inhibit PACAP-27 adenylate cyclase activation.


Subject(s)
Cell Membrane/metabolism , Neuropeptides/metabolism , Pancreas/metabolism , Receptors, Cell Surface/metabolism , Animals , Cell Line , Kinetics , Pituitary Adenylate Cyclase-Activating Polypeptide , Rats
11.
Eur J Biochem ; 195(2): 535-41, 1991 Jan 30.
Article in English | MEDLINE | ID: mdl-1997328

ABSTRACT

PACAP (pituitary adenylate-cyclase-activating peptide)-binding receptors were investigated in membranes from the rat pancreatic acinar cell line, AR 4-2J, the rat hippocampus and the human neuroblastoma cell line NB-OK, by 125I-PACAP(1-27) (amino acid residues 1-27 of N-terminal amidated PACAP) binding and adenylate cyclase activation. The relative binding of 125I-PACAP(1-27) to the receptor, and ability to activate adenylate cyclase were PACAP greater than or equal to PACAP(1-27) greater than PACAP(2-38) greater than PACAP(1-9)-VIP(10-28)(PACAP-VIP) greater than PACAP(2-27) greater than [Ser9,Tyr13]VIP greater than [Tyr13]VIP greater than or equal to [Ser9]VIP greater than or equal to VIP(1-23)-PACAP(24-27)(VIP-PACAP) greater than VIP (vasoactive intestinal peptide). The N-terminal moiety of PACAP(1-27) was more important than the three amino acids at the C-terminus for 125I-PACAP(1-27)-binding site recognition. For rat pancreatic 125I-VIP-binding sites tested with 125I-VIP, the order of binding affinity was PACAP = PACAP(1-27) greater than or equal to VIP = [Ser9]VIP = [Tyr13]VIP = [Ser9,Try13]VIP greater than or equal to PACAP-VIP greater than or equal to VIP-PACAP greater than PACAP(2-38) = PACAP(2-27). Pancreatic 125I-VIP-binding sites, when compared to 125I-PACAP(1-27)-binding sites, showed little specificity and only weak coupling, so that PACAP and VIP-PACAP acted only as partial VIP agonists on adenylate cyclase.


Subject(s)
Adenylyl Cyclases/metabolism , Hippocampus/enzymology , Neuroblastoma/enzymology , Neuropeptides/chemistry , Pancreatic Neoplasms/enzymology , Amino Acid Sequence , Animals , Binding Sites , Cell Membrane/enzymology , Chimera , Enzyme Activation , Humans , Molecular Sequence Data , Neurons/enzymology , Pancreatic Neoplasms/drug therapy , Pituitary Adenylate Cyclase-Activating Polypeptide , Rats , Tumor Cells, Cultured , Vasoactive Intestinal Peptide/metabolism
12.
Gastroenterology ; 97(4): 837-45, 1989 Oct.
Article in English | MEDLINE | ID: mdl-2570728

ABSTRACT

The effect of acute suppression of acid secretion induced by administration of a single dose of omeprazole (2 mg/kg body wt) on postprandial gastrin release was studied in 10 conscious dogs. In omeprazole-treated dogs, a sustained gastrin release was observed during a 10-h period after feeding, although greater than 95% of the meal had left the stomach after 4 h. This sustained gastrin release could be inhibited by acidification of the gastric lumen, by somatostatin, and by atropine. Insulin and bombesin induced considerable gastrin release in omeprazole-treated dogs, but plasma gastrin concentrations returned almost to basal values after 3 h. Omeprazole administered alone had no significant effect on basal gastrin levels. These data indicate that, in dogs, when acid secretion is suppressed by omeprazole a meal induces a sustained gastrin release lasting for up to 10 h. This gastrin release is probably related to the fact that food has been in contact with the gastric lumen, as neither vagal nor bombesin stimulation induced such a sustained activity of the G cells.


Subject(s)
Eating , Gastric Acid/metabolism , Gastrins/blood , Omeprazole/pharmacology , Animals , Atropine/pharmacology , Bombesin/pharmacology , Dogs , Hydrochloric Acid/pharmacology , Hydrogen-Ion Concentration , Insulin/pharmacology , Somatostatin/pharmacology
13.
Biochim Biophys Acta ; 1013(2): 144-51, 1989 Sep 19.
Article in English | MEDLINE | ID: mdl-2504287

ABSTRACT

L-Arginine and L-ornithine stimulate insulin release from pancreatic islets exposed to D-glucose. This coincides with an increased outflow of 86Rb and 45Ca from prelabelled islets and an increased net uptake of 45Ca by the islets. In the presence of D-glucose, L-lysine stimulates insulin secretion to the same extent as L-arginine or L-ornithine, but the hormonal release is not further enhanced by combinations of these cationic amino acids. L-Arginine or L-ornithine failed to enhance insulin release evoked by either L-leucine or 2-ketoisocaproate. The inhibitor of ornithine decarboxylase D,L-alpha-difluoromethyl ornithine failed to affect the metabolism and insulinotropic action of D-glucose in pancreatic islets, and only caused a partial inhibition of the secretory response to either L-arginine or L-ornithine. The latter amino acids inhibited modestly but significantly D-glucose utilization and oxidation by pancreatic islets. These and complementary findings suggest that the secretory response to L-arginine and L-ornithine is not attributable to any major change in the overall oxidative catabolism of nutrients, but involves mainly a biophysical component, such as the depolarization of the plasma membrane by these cationic amino acids.


Subject(s)
Arginine/pharmacology , Insulin/metabolism , Islets of Langerhans/drug effects , Ornithine/pharmacology , Animals , Arginine/metabolism , Calcium/metabolism , Dose-Response Relationship, Drug , Eflornithine/pharmacology , Glucose/pharmacology , Inositol/metabolism , Insulin Secretion , Islets of Langerhans/metabolism , Lysine/pharmacology , Ornithine/metabolism , Oxidation-Reduction , Polyamines/biosynthesis , Rats
14.
Regul Pept ; 22(3): 285-93, 1988 Aug.
Article in English | MEDLINE | ID: mdl-2902658

ABSTRACT

During a first series of experiments, the gastrin responses to a meal were measured and compared to the responses seen after administration of cimetidine (2.5 mg/kg/h) or omeprazole (2 mg/kg). During a second series of experiments the effects of cimetidine (2.5 mg/kg/h), ranitidine (0.5 mg/kg/h) and omeprazole (2 mg/kg) on post-prandial gastrin and somatostatin release were determined in experiments during which the intragastric pH was maintained close to 6.4. During a third series of experiments, the effects of cimetidine (2.5 mg/kg/h) and omeprazole (2 mg/kg) on basal gastrin and somatostatin release were estimated. Postprandial gastrin release was increased by cimetidine and by omeprazole. When acidification of the gastric content was prevented by intragastric titration, postprandial gastrin release was increased by about 100%. No further increase was observed when the animals were concomitantly treated with cimetidine, ranitidine or omeprazole. Intragastric titration did not alter postprandial somatostatin release. Concomitant administration of H2 blockers decreased the somatostatin response to the meal, while concomitant administration of omeprazole did not alter this release. No significant changes were observed in basal gastrin or somatostatin levels after administration of cimetidine or omeprazole.(ABSTRACT TRUNCATED AT 250 WORDS)


Subject(s)
Cimetidine/pharmacology , Gastrins/metabolism , Omeprazole/pharmacology , Ranitidine/pharmacology , Somatostatin/metabolism , Animals , Dogs , Food , Gastric Juice/metabolism , Wakefulness/drug effects
15.
Regul Pept ; 21(1-2): 29-36, 1988 May.
Article in English | MEDLINE | ID: mdl-2899334

ABSTRACT

In 4 conscious dogs with gastric fistulas the somatostatin responses to a meal were measured and compared to the responses seen after i.v. infusion of atropine sulfate (20 and 50 micrograms.kg-1.h-1) or cimetidine (8 mg.kg-1.h-1). The experiments were repeated after truncal vagotomy. The somatostatin responses to bombesin (0.5 micrograms.kg-1.h-1) were also measured before and after vagotomy. Vagotomy decreased basal and postprandial somatostatin levels and reduced the somatostatin responses to feeding during the first 30-min period following the ingestion of the meal but not during subsequent periods. Bombesin-induced somatostatin release was increased after vagotomy. Atropine decreased the somatostatin responses to the meal before and after vagotomy. Cimetidine had no significant effect. These studies suggest that, in conscious dogs, somatostatin released into the circulation is partly under vagal control and that, as for gastrin release, vagal pathways for stimulation and inhibition are present. Our studies also suggest that cholinergic mechanisms are involved in the control of postprandial somatostatin release.


Subject(s)
Atropine/pharmacology , Eating , Somatostatin/metabolism , Vagotomy , Animals , Bombesin/pharmacology , Cimetidine/pharmacology , Dogs , Gastric Acid/metabolism , Gastric Mucosa/drug effects , Insulin/pharmacology , Reference Values , Somatostatin/blood
16.
Experientia ; 43(11-12): 1216-8, 1987 Dec 01.
Article in English | MEDLINE | ID: mdl-2891561

ABSTRACT

In isolated perfused rat pancreases, the alpha-anomer of D-glucose is more potent than beta-D-glucose not solely in stimulating insulin release and suppressing glucagon output, but also in causing somatostatin secretion.


Subject(s)
Glucose/pharmacology , Pancreas/metabolism , Somatostatin/metabolism , Animals , Female , Glucagon/metabolism , Insulin/metabolism , Insulin Secretion , Kinetics , Pancreas/drug effects , Rats , Rats, Zucker , Stereoisomerism , Structure-Activity Relationship
17.
Gastroenterology ; 91(2): 333-7, 1986 Aug.
Article in English | MEDLINE | ID: mdl-2873074

ABSTRACT

The relationship between the stimulation state of the parietal cells and the gastric antisecretory properties of omeprazole has been evaluated in dogs with gastric fistulas maximally stimulated with pentagastrin. Intravenous administration of omeprazole (5 mumol/kg) 4 h before the start of stimulation with pentagastrin inhibited the acid response by 71%. This inhibition was prevented when omeprazole was given during an infusion of somatostatin at a dose that completely inhibited acid secretion. When given 18 h before stimulation with pentagastrin, omeprazole inhibited the acid response by 50%. This inhibitory effect was almost completely suppressed when omeprazole was administered during an infusion of somatostatin or after the administration of cimetidine, and was increased when omeprazole was given during an infusion of pentagastrin. These data indicate that the inhibitory effect of omeprazole given by rapid intravenous injection is related to the activity of the parietal cells at the moment of administration of the drug. They suggest that, in the intact animal as well as in the isolated gastric glands, the uptake of omeprazole by the parietal cells is related to the stimulation state of these cells.


Subject(s)
Anti-Ulcer Agents/pharmacology , Benzimidazoles/pharmacology , Gastric Acid/metabolism , Parietal Cells, Gastric/metabolism , Animals , Cimetidine/pharmacology , Dogs , Drug Interactions , Omeprazole , Parietal Cells, Gastric/drug effects , Pentagastrin/pharmacology , Somatostatin/pharmacology
18.
Dig Dis Sci ; 31(4): 418-21, 1986 Apr.
Article in English | MEDLINE | ID: mdl-3956338

ABSTRACT

The effects of sham feeding and of cimetidine, an inhibitor of gastric acid secretion, used alone or in combination on the gastric emptying of liquids were studied in four dogs fitted with a gastric fistula and a Komarov esophagostomy. Gastric emptying of a 290-ml water meal was slowed by sham feeding but not by cimetidine. Our experiments indicate that, in dogs, sham feeding slows gastric emptying of liquids by a mechanism independent of the acid secretion induced by vagal stimulation.


Subject(s)
Eating , Gastric Emptying , Vagus Nerve/physiology , Animals , Cimetidine/pharmacology , Dogs , Gastric Acid/metabolism , Gastric Emptying/drug effects , Gastrointestinal Contents , Phenolsulfonphthalein
19.
FEBS Lett ; 190(1): 142-6, 1985 Oct 07.
Article in English | MEDLINE | ID: mdl-4043392

ABSTRACT

Helodermin is a biologically active peptide isolated from the venom of the Gila monster lizard (Heloderma suspectum) whose structure is related to that of vasoactive intestinal peptide and secretin. Using a specific radioimmunoassay based on antisera prepared by immunizing rabbits with natural helodermin, we demonstrated the presence of helodermin-like material in mammalian salivary glands, including parotid, submaxillary and sublingual glands from rat and dog, and parotid and submaxillary glands from man. All helodermin-like materials had an apparent molecular mass of 4-12 kDa. Dog saliva, collected after pilocarpine stimulation, revealed similar immunoreactivity with a major component around 6 kDa.


Subject(s)
Peptides/analysis , Saliva/analysis , Salivary Glands/analysis , Secretin/analysis , Vasoactive Intestinal Peptide/analysis , Amino Acid Sequence , Animals , Chromatography, Gel , Dogs , Humans , Intercellular Signaling Peptides and Proteins , Radioimmunoassay , Rats , Species Specificity
SELECTION OF CITATIONS
SEARCH DETAIL
...